Literature DB >> 8215288

Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.

L L Dever1, J H Jorgensen, A G Barbour.   

Abstract

The in vitro activities of the macrolide antibiotics clarithromycin, 14-hydroxy-clarithromycin, azithromycin, and erythromycin against 19 isolates of Borrelia burgdorferi were investigated. MICs ranged from 0.003 to 0.03 microgram of clarithromycin per ml, 0.007 to 0.03 microgram of 14-hydroxyclarithromycin per ml, 0.003 to 0.03 microgram of azithromycin per ml, and 0.007 to 0.06 microgram of erythromycin per ml. Time-kill studies using the B31 strain of B. burgdorferi demonstrated a > or = 3-log10-unit killing after 72 h with each of the macrolide antibiotics tested in concentrations representing twice the respective MICs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215288      PMCID: PMC188047          DOI: 10.1128/AAC.37.8.1704

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  A perspective on the treatment of Lyme borreliosis.

Authors:  B J Luft; P D Gorevic; J J Halperin; D J Volkman; R J Dattwyler
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

Review 2.  Lyme disease: recommendations for diagnosis and treatment.

Authors:  D W Rahn; S E Malawista
Journal:  Ann Intern Med       Date:  1991-03-15       Impact factor: 25.391

3.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 5.  Tissue-directed pharmacokinetics.

Authors:  J J Schentag; C H Ballow
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

6.  Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria.

Authors:  M Vaara
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

7.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

8.  Treatment of early Lyme disease.

Authors:  E M Massarotti; S W Luger; D W Rahn; R P Messner; J B Wong; R C Johnson; A C Steere
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

Review 9.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 10.  Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo.

Authors:  R C Johnson
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct
View more
  6 in total

1.  Erythromycin resistance in Borrelia burgdorferi.

Authors:  Darya Terekhova; Marina L Sartakova; Gary P Wormser; Ira Schwartz; Felipe C Cabello
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 2.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 4.  Diagnosis, treatment, and prevention of Lyme disease in children.

Authors:  Stephen C Eppes
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

6.  In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.

Authors:  M Cinco; D Padovan; G Stinco; G Trevisan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.